Organon & Co.
IndexS&P 500 P/E6.23 EPS (ttm)3.59 Insider Own0.06% Shs Outstand254.37M Perf Week0.58%
Market Cap5.71B Forward P/E4.74 EPS next Y4.72 Insider Trans0.00% Shs Float254.22M Perf Month-9.97%
Income917.00M PEG- EPS next Q1.12 Inst Own78.60% Short Float / Ratio2.86% / 3.37 Perf Quarter-20.83%
Sales6.17B P/S0.92 EPS this Y-32.40% Inst Trans-0.05% Short Interest7.28M Perf Half Y-21.74%
Book/sh-3.51 P/B- EPS next Y8.15% ROA8.60% Target Price32.89 Perf Year-34.80%
Cash/sh2.77 P/C8.09 EPS next 5Y-2.00% ROE-84.40% 52W Range21.11 - 39.09 Perf YTD-19.84%
Dividend1.12 P/FCF15.35 EPS past 5Y-12.80% ROI11.40% 52W High-42.72% Beta-
Dividend %5.00% Quick Ratio1.20 Sales past 5Y-10.10% Gross Margin63.00% 52W Low6.06% ATR0.79
Employees10000 Current Ratio1.60 Sales Q/Q-7.40% Oper. Margin18.20% RSI (14)31.80 Volatility3.03% 3.29%
OptionableYes Debt/Eq- EPS Q/Q-46.70% Profit Margin14.90% Rel Volume1.05 Prev Close21.67
ShortableYes LT Debt/Eq- EarningsFeb 16 BMO Payout31.00% Avg Volume2.16M Price22.39
Recom2.60 SMA20-6.96% SMA50-19.13% SMA200-21.77% Volume2,262,917 Change3.32%
Mar-16-23Initiated Raymond James Outperform $33
Oct-14-22Downgrade BofA Securities Neutral → Underperform $27 → $25
Sep-06-22Upgrade Piper Sandler Neutral → Overweight $37 → $34
Aug-05-22Downgrade BofA Securities Buy → Neutral $40 → $37
Apr-27-22Initiated Goldman Buy $40
Apr-06-22Resumed Morgan Stanley Equal-Weight $35
Oct-07-21Initiated Piper Sandler Neutral $35
Sep-01-21Initiated BofA Securities Buy $43
Jul-22-21Initiated Citigroup Buy $35
Jun-15-21Initiated JP Morgan Neutral $38
Show Previous Ratings
Mar-07-23 07:00AM
Mar-03-23 07:30AM
Feb-27-23 07:30AM
Feb-16-23 07:30AM
Feb-13-23 06:43AM
07:30AM Loading…
Feb-06-23 07:30AM
Jan-27-23 12:10PM
Jan-05-23 07:30AM
Dec-15-22 07:30AM
Dec-12-22 08:00AM
Nov-15-22 07:30AM
Nov-14-22 07:40AM
Nov-07-22 07:30AM
07:30AM Loading…
Nov-03-22 07:30AM
Oct-20-22 07:30AM
Sep-26-22 07:00AM
Aug-17-22 07:30AM
Aug-07-22 08:29AM
Aug-04-22 07:30AM
Jul-28-22 07:30AM
Jul-25-22 10:24AM
Jul-21-22 07:30AM
Jun-30-22 08:00AM
Jun-13-22 08:30AM
Jun-09-22 11:34AM
Jun-02-22 07:31AM
10:45AM Loading…
May-10-22 10:45AM
May-05-22 07:30AM
Apr-21-22 07:30AM
Apr-13-22 06:30AM
Apr-05-22 01:07PM
Mar-31-22 07:00AM
Mar-29-22 07:00AM
Mar-19-22 08:55AM
Mar-17-22 10:45AM
Mar-02-22 07:00AM
Mar-01-22 06:55AM
Feb-20-22 07:20AM
Feb-17-22 06:30AM
Feb-16-22 08:30AM
Feb-15-22 01:56PM
Feb-08-22 09:38AM
Feb-07-22 06:38PM
Feb-04-22 05:38PM
Feb-03-22 01:38PM
Feb-02-22 09:38AM
Feb-01-22 07:30AM
Jan-31-22 09:38PM
Jan-28-22 05:38PM
Jan-27-22 09:38AM
Jan-26-22 05:38PM
Jan-21-22 01:38PM
Jan-19-22 01:38PM
Jan-18-22 05:38PM
Jan-13-22 05:38PM
Jan-11-22 07:00AM
Jan-10-22 01:38PM
Jan-07-22 01:38PM
Jan-05-22 01:38PM
Jan-03-22 09:38PM
Dec-26-21 04:38AM
Dec-20-21 05:38PM
Dec-18-21 11:38PM
Dec-17-21 10:38AM
Dec-13-21 11:38PM
Dec-11-21 02:38AM
Dec-09-21 01:38PM
Nov-11-21 06:31AM
Nov-08-21 02:04PM
Oct-28-21 07:30AM
Oct-15-21 06:50AM
Oct-11-21 07:30AM
Sep-22-21 06:00AM
Sep-21-21 12:01AM
Sep-01-21 08:15AM
Organon & Co., a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive. The company's biosimilars portfolio consists of three immunology products, such as Brenzys, Renflexis, and Hadlima, as well as two oncology products, including Ontruzant and Aybintio. It also offers cardiovascular products, consisting of several cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for various treatments to control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. In addition, the company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. The company sells its products primarily to drug wholesalers and retailers, hospitals, and government agencies, as well as managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was incorporated in 2020 and is based in Jersey City, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
DiMarco KathrynCorporate ControllerFeb 09Option Exercise0.001,86904,615Feb 10 06:04 PM